Key Updates
WMT declined 2.21% since the 22 September report, retreating from $109.68 to $107.26 and erasing the prior rebound. The stock remains range-bound between the post-earnings trough of $104.87 (1 September) and the recent high of $109.69 (22 September), reflecting continued investor indecision following the mixed fiscal Q2 2027 results. No new earnings or guidance events occurred since the last report; the principal new development is a 23 September Morningstar note reaffirming Walmart's wide-moat rating based on scale and omnichannel leadership, though the firm's separate valuation call (2-star, $81 fair value) from late August continues to signal the shares are moderately overvalued at current levels.
Current Trend
- YTD performance: -3.72%, with a sharper 6-month decline of -12.84% driven primarily by the post-Q2-earnings selloff on 20 August.
- Short-term action is mixed: 1-day -0.31%, 5-day +0.50%, 1-month +2.80%, indicating a stabilizing but fragile base after the August drop.
- Price is consolidating within the $104.87–$109.69 range established since early September, with $107.26 sitting near the midpoint.
Investment Thesis
The long-term thesis rests on Walmart's structural moat: dominant scale (~two-thirds of the superstore/warehouse club market), a leading 31% share of online grocery, and an expanding high-margin advertising and membership ecosystem projected to reach 41% of operating profit by fiscal 2036 (Morningstar). International growth, particularly in China, and new adjacent revenue streams such as restaurant delivery support the diversification narrative (Fortune, CNBC).
Thesis Status
The thesis remains structurally intact but is under near-term pressure. Q2 FY2027 revenue grew 6% YoY to $186.1 billion, yet net income fell 9% and diluted EPS declined 9% to $0.80, evidencing margin compression from tariff-related items and a 125-basis-point pharmacy pricing headwind (SEC 10-Q, Morningstar). U.S. comparable sales growth slowed to 2.6%, the lowest since 2020. Morningstar's reaffirmed wide-moat rating (Morningstar) supports the long-term competitive positioning, but the firm's $81 fair value estimate against the current $107.26 price implies the market continues to price in optimistic execution on margin expansion that has yet to materialize in reported earnings.
Key Drivers
- Mixed Q2 FY2027 results: revenue +6% YoY, net income and EPS -9% YoY (SEC EDGAR).
- Tariff refund provided a temporary 7-point boost to adjusted operating income, masking underlying margin pressure (Morningstar).
- Advertising business ($6.4B in sales, ~70% margins) continues to scale as a profit driver (Morningstar).
- China segment delivered 20.7% sales growth, materially outpacing the U.S. business (Fortune).
- Restaurant delivery expansion (Dunkin', Subway) broadens the logistics-driven revenue base (CNBC, Business Insider).
- Opioid lawsuit settlement with the DOJ removes a legacy legal overhang (CNBC).
- 23 September Morningstar analysis reaffirms Walmart's wide economic moat based on scale and digital penetration (Morningstar).
Technical Analysis
WMT trades at $107.26, within the established $104.87–$109.69 consolidation range formed since the 20 August earnings-driven selloff. The stock has failed to hold above resistance at $109.69 (22 September high), pulling back 2.21% toward the range midpoint. Support sits at $104.87 (1 September post-earnings low). Short-term momentum is neutral-to-negative (1-day -0.31%), while the 1-month trend remains modestly positive (+2.80%), suggesting a basing pattern rather than a decisive breakout. The broader 6-month downtrend (-12.84%) remains the dominant technical backdrop, and a break below $104.87 would signal renewed downside risk toward earlier 2026 lows.
Bull Case
- Wide-moat reaffirmation: dominant scale with ~two-thirds share of superstore/warehouse club market and 31% online grocery share, supporting durable competitive advantage (Morningstar).
- High-margin advertising business tripled in four years to $6.4B in sales at ~70% margins, with upgraded long-term projections contributing to a raised fair value estimate (Morningstar, Morningstar).
- China business grew 20.7%, with over 50% of sales now online, demonstrating successful international omnichannel execution (Fortune).
- Consolidated revenue grew 6% YoY to $186.1 billion despite margin headwinds, indicating continued top-line resilience (SEC EDGAR).
- Resolution of the DOJ opioid lawsuit removes a multi-year legal overhang, following the prior $3.1 billion state settlement (CNBC).
Bear Case
- Valuation concern: Morningstar rates WMT 2-star with an $81 fair value estimate, implying the stock is moderately overvalued at $107.26 (Morningstar).
- Net income and diluted EPS fell 9% YoY in Q2 FY2027 despite revenue growth, signaling margin compression (SEC EDGAR).
- U.S. comparable sales growth slowed to 2.6%, the weakest pace since 2020, indicating decelerating core demand (Morningstar).
- Pharmacy pricing legislation created a 125-basis-point margin headwind, with adjusted operating income growth partly dependent on a one-time 7% tariff refund boost (Morningstar).
- Sustained price weakness: shares down 4.8% YTD as of early September and 12.84% over six months, reflecting persistent investor concern over earnings quality (Morningstar).